spitomin 10 mg tabletes
egis pharmaceuticals plc, hungary - buspirona hidrohlorīds - tablete - 10 mg
spitomin 5 mg tabletes
egis pharmaceuticals plc, hungary - buspirona hidrohlorīds - tablete - 5 mg
dalsan 20 mg apvalkotās tabletes
egis pharmaceuticals plc, hungary - citaloprāms - apvalkotās tabletes - 20 mg
dalsan 10 mg apvalkotās tabletes
egis pharmaceuticals plc, hungary - citaloprāms - apvalkotās tabletes - 10 mg
dalsan 40 mg apvalkotās tabletes
egis pharmaceuticals plc, hungary - citaloprāms - apvalkotās tabletes - 40 mg
linezolid medana 2 mg/ml šķīdums infūzijām
medana pharma sa, poland - linezolīds - Šķīdums infūzijām - 2 mg/ml
ritonavir accord 100 mg apvalkotās tabletes
accord healthcare b.v., netherlands - ritonavīrs - apvalkotā tablete - 100 mg
linezolid norameda 2 mg/ml šķīdums infūzijām
norameda uab, lithuania - linezolīds - Šķīdums infūzijām - 2 mg/ml
linezolid polpharma 600 mg apvalkotās tabletes
pharmaceutical works polpharma sa, poland - linezolīds - apvalkotās tabletes - 600 mg
zydelig
gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.